WHAT IS THYROSEQV3® AND HOW CAN IT HELP PATIENTS?
ThyroSeqV3® Genomic Classifier (GC) is a molecular test specifically designed to determine if a thyroid nodule is benign (not cancer) or malignant (cancer) when cytology result is indeterminate. ThyroSeqV3® also provides specific information about the genetic makeup of the nodule which allows physicians to determine an individualized course of treatment. If a ThyroSeqV3® result is negative, the patient can likely avoid surgical removal of their thyroid. If the result is positive, ThyroSeqV3® provides additional information that helps the physician select the most appropriate surgery, which may include preserving part of the patient’s thyroid, protecting natural thyroid function. For nodules with malignant cytology (Bethesda VI), ThyroSeqV3® can help inform the extent of surgery and targeted therapy selection. For benign cytology nodules (Bethesda II) with clinical suspicion for malignancy, ThyroSeqV3® may help clarify diagnosis.
HOW DOES THYROSEQV3® WORK?
The ThyroSeqV3® test was designed by expert physicians in the field of thyroid cancer. The test combines years of scientific and clinical experience to help personalize patient care.
- The leading platform for comprehensive genotyping of thyroid nodules.
- Interrogates 112 genes for four main classes of molecular alterations
- Utilizes a proprietary Genomic Classifier (GC) that relies on the algorithmic analysis of all detected genetic alterations to report the test result as Positive or Negative.
- Results include a specific probability of cancer, potential management, and risk of recurrence.
- Validated in the largest prospective, double-blind, multicenter study of any commercially available molecular thyroid test.
- Highest NPV and PPV among well validated tests
- Reliable detection of all types of thyroid tumors including Hürthle cell cancer, medullary thyroid cancer, and parathyroid lesions.